Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer, Effective 01/04/2023

Upload date
28 Dez, 2022

Changes to the medical criteria for the Breast Cancer Index, MammaPrint and MammaPrint NGS tests. The DCISionRT®, CPT code 0295U, will be added to this policy and is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products.

21 Dez, 2022